Evaluation of benapryzine in psychotic patients treated with phenothiazines.
D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001561:Benzilates / Q000009:adverse effects / Q000627:therapeutic use*; D005021:Ethylamines / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000009:adverse effects / Q000627:therapeutic use; D010302:Parkinson Disease, Secondary / Q000139:chemically induced / Q000188:drug therapy*; D010640:Phenothiazines; D010865:Pilot Projects; D011437:Propylamines / Q000009:adverse effects / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy; D012563:Schizophrenia, Paranoid / Q000188:drug therapy
D014150:Antipsychotic Agents; D001561:Benzilates; D005021:Ethylamines; D010276:Parasympatholytics; D010640:Phenothiazines; D011437:Propylamines